TYRA Stock Price, Tyra Biosciences, Inc. Quote, Chart

Market Summary

USD16.00-0.38

Market Closed

-2.32%

TYRA Stock Price

View Fullscreen

TYRA RSI Chart

TYRA Valuation

Market Cap

840.3M

Price/Earnings (Trailing)

-12.16

Price/Free Cashflow

-16.51

TYRA Price/Earnings (Trailing)

TYRA Profitability

Return on Equity

-33.85%

Return on Assets

-30.61%

Free Cashflow Yield

-6.06%

TYRA Fundamentals

TYRA Earnings

Earnings (TTM)

-69.1M

Earnings Growth (Yr)

-77.05%

Earnings Growth (Qtr)

-7.93%

Breaking Down TYRA Revenue

Last 7 days

10.7%

Last 30 days

-2.8%

Last 90 days

19.9%

Trailing 12 Months

27.7%

How does TYRA drawdown profile look like?

TYRA Financial Health

Current Ratio

13.8

TYRA Investor Care

Shares Dilution (1Y)

2.04%

Diluted EPS (TTM)

-1.62

Tracking the Latest Insider Buys and Sells of Tyra Biosciences, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 15, 2024	tada hiroomi	acquired	12,947	6.579	1,968	chief medical officer
Mar 15, 2024	harris todd	acquired	12,368	6.579	1,880	president and ceo
Mar 15, 2024	fuhrman alan	acquired	11,629	12.478	932	chief financial officer
Mar 11, 2024	bensen daniel	sold	-4,000	20.00	-200	chief operating officer
Mar 07, 2024	bensen daniel	sold	-1,360	20.00	-68.00	chief operating officer
Mar 06, 2024	bensen daniel	sold	-34,819	20.092	-1,733	chief operating officer
Mar 05, 2024	bensen daniel	sold	-23,802	20.0189	-1,189	chief operating officer
Mar 04, 2024	bensen daniel	sold	-101,654	20.0778	-5,063	chief operating officer
Mar 01, 2024	bensen daniel	sold	-58,111	20.0386	-2,900	chief operating officer
Feb 29, 2024	bensen daniel	sold	-41,003	20.0016	-2,050	chief operating officer

Which funds bought or sold TYRA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	FISHMAN JAY A LTD/MI	new	-	246,000	246,000	0.03%
Apr 23, 2024	AMALGAMATED BANK	reduced	-70.66	-13,000	7,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	616	106,673	-%
Apr 15, 2024	Legato Capital Management LLC	new	-	332,248	332,248	0.04%
Apr 15, 2024	EXCHANGE TRADED CONCEPTS, LLC	added	68.43	131,265	263,269	0.01%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%
Apr 05, 2024	Canaan Partners XI LLC	unchanged	-	11,245,500	72,323,900	79.77%
Apr 05, 2024	GAMMA Investing LLC	unchanged	-	48.00	262	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	unchanged	-	4.00	803	-%
Mar 11, 2024	VANGUARD GROUP INC	added	3.6	424,012	10,511,700	-%

Are Funds Buying or Selling TYRA?

Are funds buying TYRA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own TYRA

No. of Funds

Unveiling Tyra Biosciences, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 11, 2024	fmr llc	-	0	SC 13G/A
Feb 14, 2024	biotechnology value fund l p	3.4%	1,463,115	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 08, 2024	boxer capital, llc	12.3%	6,448,359	SC 13D/A
Feb 06, 2024	ra capital management, l.p.	19.99%	10,475,489	SC 13D/A
Feb 09, 2023	fmr llc	-	0	SC 13G/A
Jun 16, 2022	boxer capital, llc	15.1%	6,323,359	SC 13D/A
Mar 24, 2022	biotechnology value fund l p	3.2%	1,345,011	SC 13G
Feb 09, 2022	fmr llc	-	0	SC 13G
Feb 08, 2022	canaan xi l.p.	9.5%	3,936,595	SC 13G

Recent SEC filings of Tyra Biosciences, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	EFFECT	EFFECT
Apr 18, 2024	ARS	ARS
Apr 18, 2024	DEF 14A	DEF 14A
Apr 18, 2024	DEFA14A	DEFA14A
Apr 05, 2024	PRE 14A	PRE 14A
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	S-8	Employee Benefits Plan
Mar 19, 2024	S-3	S-3
Mar 19, 2024	8-K	Current Report
Mar 19, 2024	4	Insider Trading

Peers (Alternatives to Tyra Biosciences, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	41.6B	6.8B	-1.39%	-19.31%	-8.82	6.07	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-5.44%	-28.86%	-41.14	9.91	76.23%	61.08%
BMRN	17.2B	2.4B	5.41%	-4.57%	102.64	7.11	15.42%	18.43%
INCY	11.6B	3.7B	-9.99%	-29.65%	19.44	3.14	8.87%	75.42%
MID-CAP
APLS	6.0B	396.6M	-10.10%	-42.90%	-11.39	15.18	425.83%	18.94%
BBIO	4.4B	-	-14.83%	70.74%	-6.74	60.35	54.84%	-34.79%
AXSM	3.4B	270.6M	-7.99%	-0.08%	-14.09	12.46	440.80%	-27.84%
ARWR	2.9B	240.7M	-16.49%	-30.64%	-9.72	12.18	-1.03%	-92.09%
ACAD	2.7B	726.4M	-7.01%	-17.50%	-44.6	3.76	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.67%	-6.03%	24.96	4.48	85.90%	-14.05%
NVAX	580.8M	983.7M	-13.72%	-45.61%	-1.07	0.59	-50.36%	17.16%
CRBP	372.9M	881.7K	-0.25%	294.45%	-8.36	466.16	-77.61%	-5.33%
INO	237.4M	4.9M	-18.06%	3.25%	-1.76	48.79	-54.97%	51.71%
IBIO	6.6M	2.1M	70.91%	57.98%	-0.24	2.14	-13.45%	66.37%

Tyra Biosciences, Inc. News

Latest updates

Tyra Biosciences, Inc. Earnings Report: Key Takeaways & Analysis

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet											(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q4
Assets	-5.2%	226	238	250	255	266	276	287	299	307	316	-
Current Assets	-5.8%	212	225	241	247	257	267	277	294	304	314	15.00
Cash Equivalents	-73.1%	58.00	216	232	242	251	263	275	292	302	313	15.00
Net PPE	41.9%	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00
Liabilities	33.4%	22.00	16.00	11.00	6.00	8.00	8.00	8.00	8.00	5.00	6.00	2.00
Current Liabilities	51.1%	15.00	10.00	5.00	4.00	6.00	5.00	5.00	5.00	4.00	5.00	2.00
Shareholder's Equity	-8.1%	204	222	239	249	258	268	279	291	302	310	-
Retained Earnings	-16.1%	-164	-142	-120	-107	-95.70	-82.80	-70.29	-55.20	-40.37	-30.44	-14.08
Additional Paid-In Capital	1.2%	369	364	359	356	354	351	349	346	342	340	0.00
Shares Outstanding	0.2%	43.00	43.00	43.00	43.00	42.00	42.00	42.00	42.00	41.00	5.00	2.00
Float	-	-	-	267	-	-	-	122	-	-	299	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)														(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3
Cashflow From Operations	21.1%	-13,532	-17,145	-9,615	-9,847	-11,980	-12,212	-17,168	-8,925	-9,028	-5,578	-4,461	-4,678	-	-
Share Based Compensation	-4.4%	4,186	4,377	2,529	2,433	2,909	1,019	2,688	3,972	1,868	507	338	174	-	-
Cashflow From Investing	-173921.7%	-144,438	-83.00	-43.00	-41.00	-21.00	-48.00	-251	-239	-105	-240	-240	-60.00	-	-
Cashflow From Financing	-30.6%	324	467	370	376	3.00	364	27.00	238	-1,508	183,437	-733	130,152	-	-

TYRA Income Statement

2023-12-31

Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development	$ 62,518	$ 43,008
General and administrative (including related party amounts of $0 and $765, respectively)	17,427	15,919
Total operating expenses	79,945	58,927
Loss from operations	(79,945)	(58,927)
Other income (expense):
Interest income	10,850	3,652
Other expense	(39)	(50)
Total other income, net	10,811	3,602
Net loss	(69,134)	(55,325)
Unrealized gain on marketable securities available-for-sale	381	0
Comprehensive loss	$ (68,753)	$ (55,325)
Net loss per share, basic	$ (1.62)	$ (1.32)
Net loss per share, diluted	$ (1.62)	$ (1.32)
Weighted - average shares used to compute net loss per common share - basic	42,704,876	41,883,904
Weighted - average shares used to compute net loss per common share - diluted	42,704,876	41,883,904

TYRA Balance Sheet

2023-12-31

Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 58,006	$ 251,213
Marketable securities	145,463	0
Prepaid and other current assets	8,202	6,075
Total current assets	211,671	257,288
Restricted cash	1,000	1,000
Property and equipment, net	1,628	1,077
Right-of-use asset	6,526	2,466
Other long-term assets	5,032	4,350
Total assets	225,857	266,181
Current liabilities:
Accounts payable	4,662	1,145
Lease liabilities, current	280	140
Accrued and other current liabilities (including related party amounts of $0 and $59, respectively)	10,391	4,416
Total current liabilities	15,333	5,701
Lease liabilities, noncurrent	6,216	2,482
Other long-term liabilities	46	169
Total liabilities	21,595	8,352
Commitments and contingencies (Note 10)
Stockholders' equity:
Preferred stock, $0.0001 par value; 50,000,000 shares authorized at December 31, 2023 and December 31, 2022; no shares issued and outstanding at December 31, 2023 and December 31, 2022	0	0
Common stock, $0.0001 par value; 500,000,000 shares authorized at December 31, 2023 and December 31, 2022; 43,055,393 and 42,634,459 shares issued at December 31, 2023 and December 31, 2022, respectively, and 42,928,884 and 42,353,550 shares outstanding at December 31, 2023 and December 31, 2022, respectively.	4	4
Additional paid-in capital	368,707	353,521
Accumulated other comprehensive income	381	0
Accumulated deficit	(164,830)	(95,696)
Total stockholders' equity	204,262	257,829
Total liabilities and stockholders' equity	$ 225,857	$ 266,181

About Tyra Biosciences, Inc.

Tyra Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing next-generation precision medicines for fibroblast growth factor receptor (FGFR) biology. The company offers SNÃƒâ€¦P, an in-house precision medicine platform which precise drug design through iterative molecular snapshots to predict genetic alterations for developing oncology and genetically defined condition therapies. Its lead product candidate is TYRA-300, a selective inhibitor of FGFR3 which is in Phase 1/2 clinical trial for the treatment of patients with mUC and other solid tumors. The company is also developing TYRA-300 for long-term complications associated with skeletal conditions including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes. Its product pipeline also includes TYRA-200, an FGFR1/2/3 inhibitor with potency FGFR2 fusions and molecular brake mutations for bile duct and solid tumors; FGF19+/FGFR4, a FGFR4-specific inhibitor that is active in the presence of the V550 gatekeeper and the C552 Cys mutations for liver and solid tumors; and RET, a specific inhibitor that is active in the presence of the V804 gatekeeper and the G810 solvent front mutations for the treatment of lung and thyroid cancer. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

CEO	Dr. Todd Harris Ph.D.
WEBSITE	tyra.bio
INDUSTRY	Biotechnology
EMPLOYEES	38

Tyra Biosciences, Inc. Frequently Asked Questions

What is the ticker symbol for Tyra Biosciences, Inc.? What does TYRA stand for in stocks?

TYRA is the stock ticker symbol of Tyra Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Tyra Biosciences, Inc. (TYRA)?

As of Wed Apr 24 2024, market cap of Tyra Biosciences, Inc. is 840.34 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TYRA stock?

You can check TYRA's fair value in chart for subscribers.

What is the fair value of TYRA stock?

You can check TYRA's fair value in chart for subscribers. The fair value of Tyra Biosciences, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Tyra Biosciences, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TYRA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Tyra Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether TYRA is over valued or under valued. Whether Tyra Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Tyra Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TYRA.